8-K: Stereotaxis Reports Q1 2026 Results, Eyes Growth

Stereotaxis announced its first quarter 2026 financial results, highlighting regulatory approvals for new products and a strategic acquisition, while revenue declined year-over-year.

Summary

• Stereotaxis reported first quarter 2026 revenue of $6.3 million, a decrease from $7.5 million in the same period last year.
• System revenue was $1.3 million and recurring revenue was $5.0 million for Q1 2026.
• The company received U.S. FDA approval for its MAGiC catheter and clearance for its Synchrony digital operating room system.
• A definitive agreement to acquire Robocath was announced, aiming to create a leading robotic platform.
• Operating expenses were $9.8 million, including $3.1 million in non-cash charges.
• The net loss for the quarter was $5.9 million.
• Negative free cash flow was ($3.5) million, an increase from ($1.8) million in the prior year.
• The company anticipates double-digit revenue growth for the full year 2026, with revenue expected to surpass $40 million.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While significant regulatory approvals and a strategic acquisition are positive, the year-over-year decline in revenue and increased net loss are concerning.

Positives

• Received U.S. FDA approval for the MAGiC cardiac ablation catheter in January 2026.
• Received U.S. FDA clearance for the Synchrony digital surgery system in April 2026.
• Entered into a definitive agreement to acquire Robocath, creating a combined robotic platform.
• Anticipates double-digit revenue growth for the full year 2026, with revenue expected to surpass $40 million.
• Expects third and fourth quarter 2026 revenue to exceed $10 million each.
• Plans to advance its product ecosystem and achieve profitability without substantial dilution.
• Demand for MAGiC catheter exceeds supply, with manufacturing ramp-up towards 500 catheters per month by year-end.
• Cash and cash equivalents stood at $14.6 million with no debt as of March 31, 2026.

Negatives

• Total revenue for Q1 2026 decreased to $6.3 million from $7.5 million in Q1 2025.
• System revenue decreased to $1.3 million from $2.0 million year-over-year.
• Recurring revenue decreased to $5.0 million from $5.5 million year-over-year, pressured by the transition away from legacy J&J catheters.
• Operating loss was ($6.0) million, slightly up from ($5.9) million in the prior year.
• Net loss was ($5.9) million, slightly up from ($5.8) million in the prior year.
• Adjusted operating loss and adjusted net loss increased compared to the prior year quarter.
• Negative free cash flow increased to ($3.5) million from ($1.8) million in the prior year.

Risks

• Statements made are forward-looking and subject to risks, uncertainties, and other important factors that could cause actual performance to differ materially.
• The company's ability to manage expenses at sustainable levels.
• Acceptance of the company's products in the marketplace.
• The effect of global economic conditions, including tariffs, on customer purchasing ability.
• Competitive factors.
• Changes resulting from healthcare policy.
• Dependence upon third-party vendors.
• Timing of regulatory approvals.

Future Outlook

Stereotaxis anticipates double-digit revenue growth for the full year 2026, with annual revenue expected to surpass $40 million. Revenue is expected to grow sequentially over the year, with Q3 and Q4 revenue each projected to exceed $10 million. The company believes it can achieve significant growth and profitability without substantial dilution to investors.

Management Comments

• "Stereotaxis is in one of the most exciting periods of its history. We are achieving significant regulatory approvals, executing strategic acquisitions, and witnessing the initial green shoots of commercial success with our new product ecosystem."
• "The operational and commercial friction to ramp up manufacturing and implement new products makes progress gradual, but we are efficiently driving broad-based progress on many fronts in parallel towards an attractive business built on solid foundations."
• "These regulatory approvals brought to market an entirely new foundational product ecosystem that structurally changes our commercial opportunity. We essentially developed a fresh start-up company on the shoulders of our legacy technology and funded by our legacy business."
• "The transformational agreement to acquire Robocath gives Stereotaxis a fully complementary and separate robotic mechanism of action for endovascular device navigation."

Industry Context

StockSavvy.ai notes that Stereotaxis's strategic moves, including FDA approvals for its MAGiC catheter and Synchrony system, alongside the acquisition of Robocath, position it to capitalize on the growing demand for advanced surgical robotics in endovascular interventions. The company is aiming to create a comprehensive robotic platform by integrating complementary technologies.

Stakeholder Impact

• Shareholders: Potential for future growth driven by new products and acquisitions, but short-term revenue decline and increased losses may cause concern.
• Employees: Continued focus on product development and commercialization may lead to job growth, but financial performance could impact morale.
• Customers: Access to new robotic technologies (MAGiC, Synchrony) and a more integrated platform (post-Robocath acquisition) could improve treatment options and outcomes.
• Suppliers: Increased demand for MAGiC catheters may benefit suppliers involved in its manufacturing.

Next Steps

• Continue manufacturing ramp-up for MAGiC catheter towards an expected 500 catheters per month by year-end.
• Complete the acquisition of Robocath.
• Prepare for multiple GenesisX system placements.
• Focus on growing revenue sequentially over the course of 2026.
• Achieve profitability.

Key Dates

Recommendation

The company has achieved significant regulatory milestones and is pursuing a strategic acquisition that could transform its business. However, the reported decline in revenue and increased losses in the current quarter warrant a cautious approach. Investors should monitor the execution of the growth strategy and the integration of Robocath before considering a stronger position.

Keywords

Stereotaxis, Surgical Robotics, Endovascular Intervention, MAGiC Catheter, Synchrony System, Robocath Acquisition, FDA Approval, Q1 2026 Results